Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos in a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
Talk to the deal team
Senior AdvisorParis, France
Associate DirectorParis, France
Bango plc growth capital for expansion
Bango plc has raised capital to finance its expansion plans.Learn more
Narva clinics has been acquired by Narva Åderbråckscenter AB
The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.Learn more
Bright Network has completed a fundraising
Bright Network has completed a fundraising to help support its continued growth.Learn more